Novo Nordisk Data Shows Oral Semaglutide Delivers Significant Weight Loss in Phase 3 Trial

Why It Matters

The results validate an oral GLP‑1 option that rivals injectables, expanding obesity treatment options and potentially improving adherence and patient outcomes.

Key Takeaways

• Oral semaglutide 25 mg yields up to 21.6% weight loss by week 64.
• Early responders (28.8%) lose ≥10% weight within 16 weeks.
• 77% with low physical function report mobility gains versus 43% placebo.
• Semaglutide outperforms orforglipron and causes fewer GI discontinuations.
• 90% of surveyed patients prefer semaglutide’s oral treatment profile.

Pulse Analysis

The emergence of oral semaglutide marks a pivotal shift in the obesity‑treatment landscape. Historically, GLP‑1 receptor agonists have required subcutaneous injection, limiting uptake among patients hesitant about needles. By delivering the same pharmacologic potency in a tablet form, Novo Nordisk removes a key barrier to adherence, positioning the drug as a more accessible solution for the roughly 100 million American adults living with obesity. This convenience factor dovetails with broader public‑health goals to curb weight‑related comorbidities such as type 2 diabetes and cardiovascular disease.

Data from the OASIS 4 trial underscore the clinical potency of the oral formulation. Nearly one‑third of participants qualified as early responders, shedding over 10% of body weight within four months and reaching a 21.6% reduction by week 64. Even participants who did not meet early‑response criteria still achieved double‑digit weight loss, a threshold associated with meaningful metabolic improvements. Crucially, the trial demonstrated that 77% of individuals with baseline mobility limitations experienced functional gains, highlighting the drug’s impact beyond the scale and reinforcing the link between weight loss and quality‑of‑life enhancements.

From a market perspective, the oral tablet challenges emerging competitors like orforglipron, which, despite promising early data, fell short on weight‑loss magnitude and provoked higher gastrointestinal discontinuation rates. Patient preference data—90% of 800 respondents favoring semaglutide’s profile—suggests strong commercial traction. As regulators evaluate the long‑term safety of oral GLP‑1 agents, Novo Nordisk’s robust safety record and clear efficacy advantage could translate into accelerated approvals and expanded insurance coverage, reshaping prescribing patterns across primary‑care and specialty settings.